Print Page  Close Window

2017 Press Releases

Keyword Search
 
2017 | 2016 | 2015 | 2014 | 2013
June 27, 2017
Dimension Therapeutics Completes Strategic Review and Updates Corporate Priorities
Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector product candidate for OTC deficiency, expected year end 2017 IND filings for GSDIa and Hemophilia A expected in 2018 Operating expenses reduced and cash runway extended CAMBRIDGE, Mass., June 27, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, t[...]  Read More /
May 10, 2017
Dimension Therapeutics Reports First Quarter 2017 Financial Results and Provides Corporate Update
Discontinues Clinical Development of DTX101, an AAVrh10 Factor IX Gene Therapy Product Candidate for Moderate/Severe-to-Severe Hemophilia B Initial data from Phase 1/2 clinical trial of DTX301, Dimension’s lead AAV8 vector IMD product candidate for OTC Deficiency, expected 2H 2017 CAMBRIDGE, Mass., May 10, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key o[...]  Read More /
April 24, 2017
Dimension Therapeutics Announces Presentations at the Upcoming American Society for Gene and Cell Therapy (ASGCT) Annual Meeting
CAMBRIDGE, Mass., April 24, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced poster presentations that highlight technology underpinning select product candidate programs. The presentations will occur during the 20th ASGCT Annual Meeting, which is taking place in Washington, DC, May 10-13, 2017. “We are pleased th[...]  Read More /
March 09, 2017
Dimension Therapeutics Announces Full Year 2016 Financial Results and Recent Updates Across Rare and Metabolic Disease Portfolio and in HeLa Manufacturing
In December, initiated Phase 1/2 clinical trial of DTX301, Dimension’s lead IMD product candidate for OTC Deficiency; Initial data expected 2H 2017 Updates interim results from Phase 1/2 clinical program for DTX101 in hemophilia B Conference call today at 8:30 a.m. Eastern Time CAMBRIDGE, Mass., March 09, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key [...]  Read More /
March 07, 2017
Dimension Therapeutics to Hold Full Year 2016 Financial Results and Recent Program Updates Conference Call
CAMBRIDGE, Mass., March 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced that it will report financial results for the full year ended December 31, 2016, on Thursday, March 9, 2017. Following distribution of the earnings release via wire services, Dimension Therapeutics will host a live conference call and webcas[...]  Read More /
February 07, 2017
Dimension Therapeutics Elects Dr. John A. Hohneker to Its Board of Directors
CAMBRIDGE, Mass., Feb. 07, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced the election of John A. Hohneker, M.D., Executive Vice President, Head of Research and Development of FORMA Therapeutics Inc., to Dimension’s Board of Directors (the “Board”). Dr. Hohneker brings over 25 years’ global experience in pharmaceut[...]  Read More /
January 31, 2017
Dimension Announces Interim Topline Results from Ongoing Phase 1/2 Clinical Program for DTX101, Dimension’s Lead AAV Product Candidate in Development for Adult Patients with Moderate/Severe to Severe Hemophilia B
Evidence of High-Efficiency Liver Transduction with AAVrh10 Vector Sub-clinical, Asymptomatic Elevations of ALT Observed in 5 of 6 Patients CAMBRIDGE, Mass., Jan. 31, 2017 (GLOBE NEWSWIRE) -- Dimension Therapeutics, Inc. (NASDAQ:DMTX), a biopharmaceutical company advancing novel, adeno-associated virus (AAV) gene therapies targeting the liver, a key organ for human metabolism, today announced preliminary topline safety and early efficacy results of Dimension’s multi-center phase 1/2 study[...]  Read More /